Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Earnings Results

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) issued its earnings results on Monday. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04), Fidelity Earnings reports.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock opened at $3.45 on Tuesday. The stock has a market cap of $125.89 million, a P/E ratio of -5.39 and a beta of 0.05. Brainstorm Cell Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $4.70. The firm’s fifty day moving average price is $2.80 and its 200-day moving average price is $3.01.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a report on Wednesday, August 10th. They issued a “hold” rating on the stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Brainstorm Cell Therapeutics in the second quarter worth $47,000. Virtu Financial LLC bought a new position in shares of Brainstorm Cell Therapeutics in the second quarter worth $57,000. State Street Corp increased its holdings in shares of Brainstorm Cell Therapeutics by 10.8% in the first quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock worth $323,000 after purchasing an additional 9,357 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Brainstorm Cell Therapeutics by 27.5% in the first quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock worth $827,000 after purchasing an additional 53,036 shares during the period. Institutional investors own 12.28% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

(Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Further Reading

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.